Apr 28, 2021 11:00am A new Nature study has found that improving the function of the brain s drainage system, known as meningeal lymphatics (blue and green), could potentially make Biogen s Alzheimer s candidate aducanumab more effective in mice. (Sandro Da Mesquita)
One popular theory in the quest to develop cures for Alzheimer’s disease is that targeting the toxic clumps of the protein beta-amyloid in the brain that are a hallmark of the disease could ameliorate symptoms. One such anti-amyloid drug, Biogen and Eisai’s aducanumab, has shown mixed efficacy in slowing cognitive decline in two clinical trials, while several similar candidates have simply failed to register any benefit, leaving many doubtful about the strategy.
NIH-funded study in mice suggests lymphatic boost could help reduce amyloid buildup.
Study of mouse brain shows the meningeal lymphatics system (purple and pink) could help reduce amyloid. Sandro Da Mesquita, Ph.D.
Enhancing the brainâs lymphatic system when administering immunotherapies may lead to better clinical outcomes for Alzheimerâs disease patients, according to a new study in mice. Results published April 28 in
Nature suggest that treatments such as the immunotherapies BAN2401 or aducanumab might be more effective when the brainâs lymphatic system can better drain the amyloid-beta protein that accumulates in the brains of those living with Alzheimerâs. Major funding for the research was provided by the National Institute on Aging (NIA), part of the National Institutes of Health, and all study data is now freely available to the broader scientific community.
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery
USA - English
LUT014 was found to be safe and effective
LUT014 Phase 2 trial designed to include 117 patients in 20 centers in the US and Israel has been initiated
News provided by
Share this article
Share this article
TEL AVIV, Israel, April 28, 2021 /PRNewswire/ Lutris Pharma, a clinical stage biopharmaceutical company focusing on improving anti-cancer therapies by reducing dose limiting side effects, announced today that results of a Phase1 study for its lead product, LUT014, assessing the safety, tolerability, and efficacy of topically administered LUT014 for the treatment of epidermal growth factor receptor (EGFR) inhibitor-induced acneiform lesions in metastatic colorectal cancer patients, were published in
Date Time
Draining brain’s debris enhances Alzheimer’s therapies in mice
Experimental Alzheimer’s drugs have shown little success in slowing declines in memory and thinking, leaving scientists searching for explanations. But new research in mice has shown that some investigational Alzheimer’s therapies are more effective when paired with a treatment geared toward improving drainage of fluid – and debris – from the brain, according to a study led by researchers at Washington University School of Medicine in St. Louis.
The findings, published April 28 in the journal Nature, suggest that the brain’s drainage system – known as the meningeal lymphatics – plays a pivotal but underappreciated role in neurodegenerative disease, and that repairing faulty drains could be a key to unlocking the potential of certain Alzheimer’s therapies.
We Know Exercise Can Improve Our Mental Health, But What Happens When Anxiety Gets In The Way?
This study examined the relationship between anxiety and starting exercise HRAUNGetty Images
It s no secret that exercise holds the power to improve your mental strength, but with one in eight men fighting mental ill-health, the fight for a stronger mind is often an uphill battle.
On top of this, new McMaster University research has found that the coronavirus (COVID-19) pandemic has created a paradox where mental health can be both instrumental and detrimental to starting physical activity and exercise. Simply put, people want to be active but stress and anxiety often get in the way.